Search PubMed⌕ Search

Biomedical subjects

C Kattamis

Publications and source records attributed to C Kattamis.

At least 73 records · Page 4Linked to original sources

Characterization of three types of beta zero-thalassemia resulting from a partial deletion of the beta-globin gene.

Three patients heterozygous for a partial deletion of the beta-globin gene were studied: an American Black with an approximately 1.35 kb deletion, a Turkish patient with an approximately 300 nucleotide deletion, and a Greek patient with a newly discovered deletion of 44 nucleotides. The DNA was amplified by the polymerase chain reaction procedure and sequenced; only the DNA with the deletion was amplified for the patients with the approximately 1.35 kb and approximately 300 bp deletion, facilitating the interpretation of the sequencing gels. The amplified DNA fragments from these two chromosomes were also cloned into a plasmid vector and sequenced. The size of the deletion found in the Turkish patient is 290 nucleotides and includes 123, 124 or 125 nucleotides 5' to the Cap site, the 5' untranslated region, exon 1, and 25, 24, or 23 nucleotides of the first intron. The total size of the deletion of the Black patient is 1393 nucleotides including 485 (484) bp 5' to the Cap site, exon 1, intron 1, exon 2, and 413 (414) nucleotides of the second intron. The new deletion in the Greek beta-thalassemic patient was detected by direct sequencing of amplified DNA; the 44 bp deletion begins within codon 24 or between codons 24 and 25, and includes the first 26 or 27 nucleotides of intron 1. This deletion was confirmed by hybridization of amplified DNA with a specific oligonucleotide probe and by sequence analysis of amplified DNA cloned in a plasmid. A 7 bp homology sequence (GACAGGT) was found at both sides of the 290 bp deletion, while only 3 nucleotides were repeated at both sides of the 44 nucleotide deletion (GGT). No homology was found between the breakpoints of the 1393 nucleotide deletion.

Base Sequence↗

Correlation of clinical phenotype to genotype in haemoglobin H disease.

Clinical assessment, haematological studies, and globin gene mapping were performed in 21 Greek subjects with haemoglobin H disease. Clinical phenotypes ranged from mild, and virtually asymptomatic, to severe cases requiring transfusion. The severe clinical phenotype was exclusively associated with non-deletion genotypes, whereas the mild and intermediate phenotypes occurred with deletion genotypes. Patients with non-deletion genotypes had higher levels of Hb H. For deletion genotypes of haemoglobin H disease, the value of antenatal diagnosis is questionable. In non-deletion genotypes, antenatal diagnosis should be considered, because of the more severe clinical course observed in these patients.

Adolescent↗

Activity of ribonuclease H in cells of chronic B-lymphocytic leukaemia: correlation with clinical stage.

Peripheral blood mononuclear cells (PBMNC) from 23 healthy subjects and 39 patients with B-cell chronic leukaemia (B-CLL) were assayed for ribonuclease H activity using as substrate the filter-immobilized synthetic homopolymer hybrid 3H-poly(rA):poly(dT). In 69% of the leukaemia patients examined enzyme activities were above those estimated in cells from the healthy controls. The mean enzyme levels for the normal and the leukaemic samples group were (per cent substrate hydrolysis): 8.1 +/- 8.9 and 58.7 +/- 40.8, respectively, their difference being statistically highly significant (P less than 0.0001). This result does not represent homogeneity within the cells but is due to a subclass of cells within the leukaemic clone containing the enzyme, thus contributing through pool size fluctuation to the wide variations of enzyme activity observed among the patients. These cells containing high activity could not be identified with either the prolymphocytes or the large lymphocytes. The activity of ribonuclease H in the examined CLL patients correlated with disease stage (Binet) (P = 0.011) and appeared to serve as a sensitive indicator of disease progression when compared with a number of other known prognostic parameters.

Endoribonucleases↗

Clinical, haematological, and genetic studies of type 2 normal Hb A2 beta thalassaemia.

The clinical and haematological phenotype as well as chain synthesis data were studied in 35 doubly heterozygous patients with either normal Hb A2 and Hb F, type 2 beta thalassaemia and beta (high A2) thalassaemia (26 patients), or type 2 and other rare beta or delta beta variants (nine patients). Patients doubly heterozygous for type 2 and beta zero or delta beta zero thalassaemia variants had no detectable Hb A, indicating that the type 2 normal A2 beta thalassaemia is primarily the result of a beta zero gene. The clinical phenotype varied from severe thalassaemia major to mild thalassaemia intermedia, and was mainly related to the thalassaemia variant with which the type 2 normal A2 beta thalassaemia was combined, and the proportion of Hb A produced in beta + thalassaemia patients. Haematological and chain synthesis data were similar in heterozygotes with type 2 and beta zero or beta + (high A2) thalassaemia. Hb A2 levels were within the normal range (2.3 to 3.6%) though absolute values (Hb A2 per RBC) ranged from low normal (0.5 pg/RBC) to increased levels (1.0 pg/RBC.) The variation of Hb A2, as well as the presence of Hb A2 in a type 2/delta beta high F patient and the complete absence of HbA2 in a homozygous type 2 patient, indicate that there are at least two genotypes of type 2, one beta zero and the other delta beta zero. This has been recently proven by gene mapping studies. For clinicians, routine haematological and family studies are sufficient for the proper treatment and prevention of doubly heterozygous type 2 patients.

Blood Protein Electrophoresis↗

Uncommon manifestations of histiocytosis X.

Histiocytosis X is a group of disorders of uncertain etiology with a variety of manifestations that are usually related to the age of the patient. Treatment consists of local curettage, irradiation and chemotherapy. The prognosis depends on the systems involved. The oral and perioral tissues are occasionally involved and often lead to the diagnosis. We report a case with spinal cord involvement and a case of facial nerve paralysis secondary to involvement of the petrosal bone. Also included is a case of involvement of the mandibular condyle.

Bone Diseases↗

Activity and function of hybrid ribonuclease in cells of acute and chronic myelogenous leukemia.

The activity of hybrid ribonuclease (ribonuclease H) has been determined in mononuclear blood cells (lymphocytes plus monocytes) from 23 normal individuals and cells (pool of immature granulocytes, metamyelocytes and lymphocytes) from 35 untreated acute and chronic myelogenous leukemia cases. It was found that in 86% of the leukemic samples the activity of ribonuclease H was above two standard deviations from the mean activity level drawn for the group of normal samples along the 0-100% substrate hydrolysis scale. The activity of the enzyme in leukemic cells correlated linearly with the DNA-synthesizing activity of the cells in vitro and in the examined CML cases it paralleled the inverse relationship of the incorporation of tritiated thymidine into DNA to the size of the pool of immature granulocytes. In one CML patient who received chemotherapy with Myleran, the activity of ribonuclease H, high at the initiation of drug therapy, was reduced to a normal level at remission, but increased again at the stage of subsequent relapse. These findings indicate that the levels of ribonuclease H in leukemic cells reflect the proliferative activity of the population in the cases of untreated myelogenous leukemias.

Antineoplastic Agents↗

Immunological profile after splenectomy in children with beta-thalassaemia major.

The in vitro immune functions of peripheral blood lymphocytes have been studied in 12 children with beta-thalassaemia major and hypersplenism. The study was performed prior to splenectomy and on the 2nd, 6th, 15th and 30th day after splenectomy. It was found that before splenectomy, patients had low numbers of blood leucocytes, normal rosette and T3 lymphocyte counts, low T4 and normal T8 lymphocyte counts with a T4/T8 ratio below 2, impaired T lymphocyte mitogenic responses induced by PHA, increased numbers of polyvalent and monovalent B lymphocytes and normal immunoglobulin levels of IgG and IgA. After splenectomy, especially on the 2nd day, leucocytosis, a significant decrease of T cells and their subsets and a reduction of the IgM levels were found. These parameters, except the IgM levels, increased until the 30th day after splenectomy and reached presplenectomy values. On the 2nd day after splenectomy, large mononuclear cells behaving like immunocytes appeared in the peripheral blood. They had the phenotype of T3, T4, T8, B lymphocytes and OKM1 monocytes. All the large mononuclear cells increased significantly on the 6th day after splenectomy and remained elevated during the whole study (30 days). The T4/T8 ratio was increased, but no increase was found in the functional responses of T lymphocytes.

Adolescent↗

Frequency of alpha-thalassemia in Greece.

Using hematological and gene mapping techniques, a cord blood survey was carried out to estimate the frequency of alpha-thalassemia in the Greek population. Out of 227 newborns studied, 16 (7.05%) were found by gene mapping to be alpha-thalassemia 2 heterozygotes (-alpha/alpha alpha), and of these only two had increased levels of hemoglobin Bart's in the cord blood (1.2 and 2.0%). Similarly, one heterozygotes for the common Mediterranean alpha-thalassemia 1 haplotype (-/alpha alpha) and one for the 20.5-kb deletion type (-(alpha)20.5/alpha alpha) were found, showing increased levels of Bart's of 4.8 and 6.6%, respectively. Four (1.76%) heterozygotes for the triple alpha gene arrangement (alpha alpha alpha/alpha alpha) were found. One individual with a level of Bart's in the cord blood of 8% was found to be a double heterozygote for alpha-thalassemia 2 and a dysfunctional alpha gene arrangement (-alpha/-(alpha)?). These results give an overall incidence for alpha-thalassemia in the Greek population of 8.4%.

Electrophoresis, Cellulose Acetate↗

The molecular basis of HbH disease in Greece.

Globin gene mapping in 16 Greek individuals with HbH disease and their parents has demonstrated the occurrence of several HbH genotypes brought about by the interaction of two alpha zero-thalassaemia and two alpha+-thalassaemia haplotypes. Eight of the 16 patients had the genotype - -Med/-alpha 3.7, four the genotype -(alpha)20.5/-alpha 3.7 and three the genotype - -Med/alpha alpha T. In one patient the restriction data are consistent with two possible genotypes alpha alpha T/alpha alpha T or - -/alpha alpha T. It is demonstrated that HbH disease in Greece is heterogeneous, with the deletion haplotypes - -Med and -alpha 3.7 being more prevalent than the -(alpha)20.5 and non-deletion (alpha alpha T) haplotypes.

Adult↗

Concordance of a point mutation 5' to the A gamma-globin gene with A gamma beta + hereditary persistence of fetal hemoglobin in Greeks.

In the Greek A gamma beta + type of hereditary persistence of fetal hemoglobin (HPFH), adult heterozygotes produce about 20% fetal hemoglobin (HbF), which is predominantly of the A gamma chain variety. The affected beta-globin gene cluster produces near normal amounts of beta-like globin, but in a A gamma to beta ratio of 20:80 instead of 0.5:99.5. Gelinas et al and Collins et al have shown a G to A change 117 nucleotides 5' to the A gamma gene in two Greeks with A gamma beta + HPFH. To demonstrate that this change is not a neutral polymorphism, we carried out hybridization with oligonucleotide probes (19mers) specific for the normal and the mutant sequences. While normal probe identified the A gamma fragment in genomic DNA of all subjects studied, mutant probe was positive only in Greeks with A gamma beta + HPFH. In sum, 108 beta-globin gene clusters of individuals without HPFH were negative when tested with mutant probe, but all 11 affected individuals of six families with Greek A gamma beta + HPFH (two previously sequenced and four new families) were positive with mutant probe. These data support the conclusion that the -117 mutation is causative of A gamma beta + HPFH in Greeks.

Fetal Hemoglobin↗

Immunogenicity of low doses of hepatitis B vaccine in normal children.

The immunogenicity of two low doses (5 micrograms and 10 micrograms ml-1) of hepatitis B vaccine was tested in 98 non-immune children. The seroconversion rate after the third dose was 100%. High seroconversion rates were observed even after the first dose as well as progressive increase in the geometric mean titres of the converters after each dose. The geometric mean titre in International Units one month after the third dose was higher (18 276 mIU ml-1) in children vaccinated with 10 micrograms ml-1, compared to children vaccinated with 5 micrograms ml-1 (11 313 mIU ml-1). The lowest seroconversion rate after the first and second doses and the lowest final mean geometric titre was observed in children aged 11-15 years.

Adolescent↗

The triplicated alpha gene locus and beta thalassaemia.

In five families, the coinheritance of beta thalassaemia and an additional alpha gene (alpha alpha alpha/alpha alpha) have been observed. Among the beta thalassaemia heterozygotes, no phenotypic effect of the triplicated alpha gene was detected clinically or at the haematological level. Unexpectedly, however, four out of five beta thalassaemia homozygotes with alpha alpha alpha/alpha alpha gene complement had the milder clinical condition of thalassaemia intermedia and in at least one case there was evidence to suggest that this might be due to the alpha alpha alpha gene arrangement actin as an alpha thalassaemia allele.

Chromosome Mapping↗